Growth inhibition by anchorage-deficiency is associated with increased level but reduced phosphorylation of mutant p53

Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-alpha on endothelial cells

Impaired endothelial cell proliferation has been proposed to be an early, critical defect contributing to the development of atherosclerosis. Recent studies show that high plasma tumor necrosis factor (TNF)-alpha levels and low serum ascorbic acid (AA) levels correlate with atherosclerosis severity. Additionally, AA has been reported to have potential beneficial effects in preventing atherosclerosis. Based on these studies, we investigated the role of AA (< or =1mM) on TNF-alpha-mediated vascular endothelial cell growth inhibition in vitro. In accordance with previous reports, we found that TNF-alpha alone inhibited endothelial cell proliferation. Further studies revealed that AA alone enhanced endothelial cell proliferation and that AA blocked endothelial cell growth inhibition induced by TNF-alpha. By contrast, we observed no effect of AA on endothelial cell activation or nuclear entry of nuclear factor-kappaB in response to TNF-alpha. The protective effect of AA on endothelial cell proliferation was not simply the result of its antioxidant activity but did correlate with collagen IV expression by endothelial cells. AA pre-treatment of proliferating endothelial cells promoted retinoblastoma protein (Rb) phosphorylation and decreased p53 levels when compared to untreated cells. Furthermore, the addition of AA to TNF-alpha-treated proliferating endothelial cells blocked both the inhibition of retinoblastoma protein phosphorylation and enhanced p53 expression induced by TNF-alpha. Consistent with these results, we found that AA protects endothelial cells against TNF-alpha-induced apoptosis. These studies highlight the potential therapeutic role of AA in promoting endothelial cell proliferation during inflammatory conditions, such as atherosclerosis and cardiovascular disease.

Electroporation and carrier DNA cause p53 activation, cell cycle arrest, and apoptosis

Methods used in transient transfection of cells may alter cellular signaling pathways that in turn may lead to misinterpretation of the results. A variety of genotoxic agents cause the accumulation of the p53 protein leading to either apoptosis or growth arrest. Here we report the effect of electroporation and carrier DNA on the stability, cellular localization, and transcriptional activity of p53. We show that electroporation leads to p53-dependent and also p53-independent cell-cycle arrest and apoptosis. At the same time a chemical agent polyethylenimine that is also used for transient transfection of cells causes neither upregulation of p53 nor cellular response.

p53 Phosphorylation: biochemical and functional consequences

The p53 protein plays a vital role in suppressing the development of cancer. Posttranslational modification through phosphorylation has been postulated to be an important regulatory mechanism of p53 function. Data describing the role of phosphorylation in terms of its effects on several biochemical properties and cellular functions of p53 are examined in the context of how p53 might be "phospho-regulated."

Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells

We have analysed the cell-cycle arrests and cytotoxicity of the A2780 human ovarian cell line in response to geldanamycin, a benzoquinoid ansamycin that can inhibit tyrosine kinases. Geldanamycin causes a dose-dependent G2 arrest and reversible inhibition of entry into the S phase in A2780 cells. After a 3-h exposure to 0.1 microM geldanamycin, the cells show an increase in accumulation of p53 protein that is maximal at 24 h after drug exposure. Increased p53 levels can be induced in cells by DNA-damaging agents; however, using alkaline elution and sister chromatid exchange assays we detect no DNA damage induced by geldanamycin. Using dominant negative mutant TP53 transfectants of A2780 we have analysed the possible dependence of geldanamycin-induced cell-cycle arrests on the presence of functional p53. We observe no difference in cell-cycle arrests in mutant p53 transfectants known to have the p53-DNA damage-response pathway inactivated as compared with vector-alone controls. Similarly, we observe no difference in clonogenic resistance to the cytotoxicity of geldanamycin in these cells. These results suggest that geldanamycin can induce increased p53 protein by a mechanism not involving DNA damage. Furthermore, the cell-cycle arrests and cytotoxic effects of geldanamycin in these cells are not mediated by p53-dependent pathways.

Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells

Human breast cancer MCF-7 cells, growth-arrested by serum starvation, were stimulated with recombinant human insulin-like growth factor-I (IGF-I). An increase in DNA synthesis was induced 20 hr later, which was as effective as that induced by serum. The increase in DNA synthesis was significantly inhibited either by antibody to the IGF-I receptor or by the tyrosine kinase inhibitor, methyl-2,5-dihydroxycinnamate (2,5-MeC). The IGF-I-induced DNA synthesis coincided with an elevated level of phosphorylation of p53 on tyrosine and an alteration in the subcellular distribution of the protein from the nucleus to the cytoplasm. Whereas the increases in DNA synthesis and p53 phosphorylation were inhibited by antibody to the IGF-I receptor and by 2,5-Mec, the nuclear exclusion of p53 was prevented by the antibody and also, although not significantly, by 2,5-Mec. The results suggest that growth stimulation of MCF-7 cells by IGF-I is accompanied by tyrosine phosphorylation and nuclear exclusion of p53.

Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells

p53 protein was localized in the cytoplasm of growing and in the nucleus of growth-arrested MCF-7 cells. While the absolute amount and rate of synthesis of p53 in growing and arrested cells were nearly the same, the protein in growing cells was phosphorylated to a greater extent than in arrested cells. The abilities of the cytoplasmic and nuclear p53 proteins to bind to DNA sequences specific for p53 protein binding did not differ remarkably despite their differential phosphorylation levels. Serum-induced translocation of the p53 protein from the nucleus to the cytoplasm, as well as DNA and protein synthesis, were inhibited by cycloheximide. These results suggest that the DNA synthesis-associated cytoplasmic translocation of p53 protein in response to serum stimulation depends on de novo protein synthesis and not on alteration of the protein's ability to bind to specific DNA sequences.